Trial Search Results
Stereotactic Radiation Therapy for Pediatric Sarcomas
The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically effective doses have been shown to increase control in histologies, such as sarcoma, which are common in the pediatrics population. With stereotactic radiation therapy techniques, a reduction in normal tissue dose surrounding the target lesion of interest may also be accomplished resulting in lower toxicity. Given that pediatric patients with sarcomas, presenting with limited metastases in lung and bone, are still considered to be a curable population with aggressive local therapy, SBRT could have a significant impact on outcomes in oligometastatic patients who may be otherwise unresectable.
Stanford is currently accepting patients for this trial.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Radiation: SBRT
- histologically or cytologically confirmed metastatic sarcoma of the soft tissue or
- must have measurable disease
- disease must be surgically unresectable as determined by a tumor board or surgeon
- greater than 3 years of age
- less than or equal to 40 years of age
- life expectancy of at least 9 months
- adequate performance status (Lansky Performance Status greater than or equal to 50).
- ability to understand and willingness to sign informed consent document
- patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering
- patients who have had any prior radiotherapy to the treatment site(s)
- patients may not participate on any other treatment protocol while they are receiving
treatment on this protocol and for up to 3 months after these protocol treatments have
- pregnant women
- refusal of women of child bearing potential to take a pregnancy test prior to
Ages Eligible for Study
4 Years - 40 Years
Genders Eligible for Study